MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer
- PDF / 7,265,234 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 64 Downloads / 195 Views
MAGE‑C2/CT10 promotes growth and metastasis through upregulating c‑Myc expression in prostate cancer Jun Qiu1 · Bei Yang2 Received: 11 March 2020 / Accepted: 20 June 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Prostate cancer (PC) is the most common reproductive cancer in men and the third leading cause of cancer death among men worldwide. Recently targeted therapy showed a significant therapeutic effect on PC, whereas finding more PC therapeutic target is still urgently needed. Melanoma-associated antigen-encoding C2 (MAGE-C2/CT10), which have significant homology with the MAGE-C1/CT-7 gene, was known to be involved in the development of a variety of tumors. However, the role and mechanism of MAGE-C2/CT10 in prostate cancer remains unclear. Herein, we found the high levels of MAGE-C2/CT10 in highly metastatic prostate cancer. Our findings confirmed that the depletion of MAGE-C2/CT10 suppressed the growth of PC cells, and restrained PC cell migration and invasion in vitro. We noticed MAGE-C2/CT10 could stimulate c-Myc expression via FBP1, and further contributed to PC cell proliferation and motility. Performing in vivo assays, we demonstrated MAGE-C2/CT10 promoted tumor growth and metastasis of PC cells in mice. Collectively, we found the abnormal expression of MAGE-C2/CT10 in PC, and revealed the regulatory mechanism underlying MAGE-C2/CT10 promoting PC progression and metastasis. Keywords Prostate cancer (PC) · MAGE-C2/CT10 · Migration · FBP1 · c-myc
Introduction Prostate cancer (PC) is the most common reproductive cancer in men and the third leading cause of cancer death among men worldwide [1]. Although treatment options such as radical prostatectomy and radiotherapy can successfully cure most patients, about 30–40% of patients will relapse, which is the main factor affecting the survival of patients with prostate cancer [2]. In the case of advanced prostate cancer, due to its high metastasis, chemoradiotherapy and Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11010-020-03814-7) contains supplementary material, which is available to authorized users. * Bei Yang [email protected] 1
Center of Clinical Laboratory, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215000, Jiangsu, China
Department of Imaging, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Jiangan District, Wuhan 430014, Hubei, China
2
surgical resection are not effective, further increasing the mortality rate [3]. In decades, targeted therapy, as a precision therapy, has a significant therapeutic effect on prostate cancer, which is worthy of further study [4]. However, it is urgent to understand the pathogenesis of PC and find more targets for PC treatment. In most cases, the cancer/testis (CT) antigen is expressed only in the germ cells of the human testis, whereas the CT antigen (CT-X) corresponding to the X chromosome is expressed in
Data Loading...
